These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 16406098

  • 1. Pathogenicity and immunogenicity in mice of vaccinia viruses mutated in the viral envelope proteins A33R and B5R.
    Gurt I, Abdalrhman I, Katz E.
    Antiviral Res; 2006 Mar; 69(3):158-64. PubMed ID: 16406098
    [Abstract] [Full Text] [Related]

  • 2. The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence.
    Engelstad M, Smith GL.
    Virology; 1993 Jun; 194(2):627-37. PubMed ID: 8503178
    [Abstract] [Full Text] [Related]

  • 3. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.
    Galmiche MC, Goenaga J, Wittek R, Rindisbacher L.
    Virology; 1999 Feb 01; 254(1):71-80. PubMed ID: 9927575
    [Abstract] [Full Text] [Related]

  • 4. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.
    Pulford DJ, Gates A, Bridge SH, Robinson JH, Ulaeto D.
    Vaccine; 2004 Sep 03; 22(25-26):3358-66. PubMed ID: 15308360
    [Abstract] [Full Text] [Related]

  • 5. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host.
    Fang M, Cheng H, Dai Z, Bu Z, Sigal LJ.
    Virology; 2006 Feb 05; 345(1):231-43. PubMed ID: 16256161
    [Abstract] [Full Text] [Related]

  • 6. Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA).
    Abdalrhman I, Gurt I, Katz E.
    Vaccine; 2006 May 08; 24(19):4152-60. PubMed ID: 16603280
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The N-terminal domain of the vaccinia virus E3L-protein is required for neurovirulence, but not induction of a protective immune response.
    Brandt T, Heck MC, Vijaysri S, Jentarra GM, Cameron JM, Jacobs BL.
    Virology; 2005 Mar 15; 333(2):263-70. PubMed ID: 15721360
    [Abstract] [Full Text] [Related]

  • 12. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin.
    Bell E, Shamim M, Whitbeck JC, Sfyroera G, Lambris JD, Isaacs SN.
    Virology; 2004 Aug 01; 325(2):425-31. PubMed ID: 15246280
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.
    Golden JW, Josleyn MD, Hooper JW.
    Vaccine; 2008 Jun 25; 26(27-28):3507-15. PubMed ID: 18485547
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.
    Clark KM, Johnson JB, Kock ND, Mizel SB, Parks GD.
    Virology; 2011 Oct 25; 419(2):97-106. PubMed ID: 21885079
    [Abstract] [Full Text] [Related]

  • 18. Pathogeneses of respiratory infections with virulent and attenuated vaccinia viruses.
    Hayasaka D, Ennis FA, Terajima M.
    Virol J; 2007 Feb 27; 4():22. PubMed ID: 17326843
    [Abstract] [Full Text] [Related]

  • 19. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
    Kaufman DR, Goudsmit J, Holterman L, Ewald BA, Denholtz M, Devoy C, Giri A, Grandpre LE, Heraud JM, Franchini G, Seaman MS, Havenga MJ, Barouch DH.
    J Virol; 2008 Jul 27; 82(14):6829-37. PubMed ID: 18448519
    [Abstract] [Full Text] [Related]

  • 20. In vitro human CD4+ T cell response to the vaccinia protective antigens B5R and A33R.
    Sirven P, Castelli FA, Probst A, Szely N, Maillere B.
    Mol Immunol; 2009 Apr 27; 46(7):1481-7. PubMed ID: 19193441
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.